The FDA has granted fast track designation for abenacianine to help surgeons better visualize lung tumors during minimally invasive surgery. MI Cancer Seek has received approval from the FDA as a ...
ASCO 2023: Timing of PARP Inhibition for Prostate Cancer with Defects in Homologous Recombination Repair ASCO 2023: A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer ...
ASCO 2023: Discussant: THOR – Results of Erdafitinib versus Chemotherapy in Patients with Advanced or Metastatic Urothelial Cancer with Select Fibroblast Growth Factor Receptor Alterations ASCO 2023: ...
Abenacianine received fast track designation for lung cancer surgery, the combination of amivantamab and Lazertinib showed OS improvement in NSCLC, and sunvozertinib has been granted priority review ...
Sunvozertinib received FDA priority review for NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy progression. The WU-KONG1 Part B study showed a 53.3% objective response ...
The occurrence of NSCLC is not uncommon among never-smokers. These patients are more likely to be young, female, symptomatic at the time of presentation, have poorly differentiated tumors, and ...
Background: Ki-67 expression is a well-established prognostic marker in various cancers. However, Ki-67 expression is also known as being heterogeneous. We investigated the prognostic significance ...
Sunvozertinib received FDA priority review for advanced EGFR exon 20 insertion-positive non-small cell lung cancer progressing after chemotherapy. Priority review was granted by the FDA for ...
This decision follows the FDA’s earlier Breakthrough Therapy Designations for Sunvozertinib in treatment naïve and relapsed or refractory settings. Currently, no small molecule drug has been approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback